Drug Approval | April 02, 2024
AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer
Application based on results from the TROPION-Breast01 Phase III trial
Application based on results from the TROPION-Breast01 Phase III trial
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
To create leading company developing medicines targeting metalloenzymes
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
Subscribe To Our Newsletter & Stay Updated
